Clincosm LogoSign in Get a demo

PTTKT: The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation

Sponsor
West China Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05249699
Collaborator
(none)
303
Enrollment
3
Arms
16
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Organ transplant recipients are a high incidence group of tuberculosis infection, and the incidence rate is 7-27 times that of the general population. The prevention of postoperative tuberculosis infection is an important part of kidney transplant recipients postoperative follow-up. Taking reasonable tuberculosis prevention strategies for organ transplant recipients can better prevent the occurrence of postoperative tuberculosis and reduce the unreasonable use of anti-tuberculosis drugs. The previous screening methods for active tuberculosis mainly include sputum smear culture, tissue biopsy, tuberculin skin test, tuberculosis antibody, tuberculosis DNA, and chest imaging. However, there is still a lack of accurate and effective means for screening for latent tuberculosis infection. The tuberculosis interferon-γ release test has recently received more and more attention as a means of screening for potential tuberculosis infection. However, how to apply tuberculosis interferon-γ release test in clinical practice is still controversial. The investigators hope to explore the clinical application prospects and practical value of tuberculosis interferon-γ release test through this research.

According to the conclusion of the retrospective study, the investigators found that the recipients with negative TSPOT result maybe don't need follow the isoniazid treatment to prevent the development of tuberculosis even though participants have clinical risk factor of tuberculosis(include past tuberculosis history, the close contact with active tuberculosis patients, an area with a high incidence of tuberculosis, abnormal chest x ray performance ).

The investigators will divided the recipients with tuberculosis risk factors into three groups randomly. Of course, the invention require written informed consent. The first group with positive tuberculosis interferon gamma release assay (TSPOT) result will follow through with the treatment ,which is a daily dose of isoniazid for six months(300mg daily) after kidney transplant surgery. The second group with negative TSPOT result will not follow through the isoniazid treatment. The third group will follow through with the isoniazid treatment no matter their TSPOT results. The investigators will conduct a prospective clinical trial with the first aim of exploring the effectiveness of TSPOT results in kidney transplant recipients with clinical tuberculosis risk factors, and the second aim of exploring the benefit of the isoniazid treatment follow the TSPOT results rather than clinical risk factors.

Condition or Disease Intervention/Treatment Phase
  • Drug: Isoniazid
  • Other: without any additional anti-tuberculosis treatment
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
303 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation (PTTKT):Protocol for an Open-label, Prospective, Randomized, 3-arm, Controlled Trial
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Positive TSPOT results with clinical risk factors group

patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge

Drug: Isoniazid
prevent the development of tuberculosis
Placebo Comparator: Negative TSPOT results with clinical risk factors group

patients receive no additional therapy

Other: without any additional anti-tuberculosis treatment
reduce the number of Participants With Treatment-Related Adverse Events
Experimental: Clinical risk factors group

patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge

Drug: Isoniazid
prevent the development of tuberculosis

Outcome Measures

Primary Outcome Measures

  1. The primary outcome is the incidence of tuberculosis in these groups. [12 months]

    The primary objective of this study is to evaluate the incidence of tuberculosis between these groups. The incidence of tuberculosis was assessed by WHO TB guidelines 2021.

Secondary Outcome Measures

  1. The secondary outcome is subject incidence of adverse events [12 months]

    The primary objective of this study is to evaluate the safety of isoniazide among the kidney transplant recipients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. living-donor kidney transplantation;

  2. eGFR level > 45ml/min/1.73m2 at discharge;

  3. 18<Age <65years;

  4. receiving standard triad immunosuppressive regimen

Exclusion Criteria:

  1. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 or more of upper limit of normal

  2. Combined with HBV/HCV/HIV/TB infection in the donor or recipient;

  3. Malignancy history in the donor and recipient;

  4. organ transplant history in the recipient.

  5. The positive TSPOT result or past TB history in the donor

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • West China Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Tao Lin, Professor Tao Lin, West China Hospital
ClinicalTrials.gov Identifier:
NCT05249699
Other Study ID Numbers:
  • WestChinaH-PTTKT
First Posted:
Feb 22, 2022
Last Update Posted:
Apr 4, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Tuberculosis
Isoniazid
Antitubercular Agents

Study Results

No Results Posted as of Apr 4, 2022